1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantly enhances antipoliovirus systemic and mucosal immunity in mice. Although serum immunoglobulin G antibodies are significantly higher in serotypes 2 and 3, and although salivary immunoglobulin A is significantly increased in serotypes 1 and 3, DHVD3 had the most dramatic effect on the level of neutralizing serum antibodies of all 3 IPV serotypes. These findings suggest a possible use of vitamin D3 as an adjuvant for currently used and proposed new Sabin IPVs.
Ivanov
Alexander P
AP
Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD 20852, USA. ivanov@cber.fda.gov
Dragunsky
Eugenia M
EM
Chumakov
Konstantin M
KM
D000818:Animals; D004195:Disease Models, Animal; D007109:Immunity / Q000187:drug effects; D018928:Immunity, Mucosal / Q000187:drug effects*; D051379:Mice; D011051:Poliomyelitis / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D017955:Poliovirus / Q000187:drug effects / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000276:immunology; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000494:pharmacology
D011054:Poliovirus Vaccine, Inactivated; D015164:Vaccines, Inactivated; C118756:dihydroxy-vitamin D3; D014807:Vitamin D